Cryo-Cell International, Inc. CCEL

Company Overview

Cryo-Cell International, Inc. is a U.S.-based biocellular preservation company focused on the collection, processing, and long-term storage of umbilical cord blood and cord tissue stem cells. The company operates within the regenerative medicine, biotechnology services, and healthcare storage industries, serving expectant parents, healthcare providers, and emerging cell-therapy markets. Its primary revenue drivers are stem cell banking services, including upfront processing fees and recurring annual storage fees associated with preserved cord blood and tissue samples.

The company was founded in 1989 and is headquartered in Oldsmar, Florida. Cryo-Cell was among the early commercial entrants in private cord blood banking in the United States and has positioned itself around proprietary preservation technologies, long-term specimen storage infrastructure, and quality-control standards. The company markets the potential future therapeutic applications of newborn stem cells in regenerative medicine and immune-related treatments, although many clinical applications remain under ongoing medical and regulatory evaluation.

Business Operations

Cryo-Cell generates revenue primarily through its cellular processing and cryogenic storage services. Its operations include the collection, testing, processing, and preservation of umbilical cord blood and cord tissue stem cells for long-term family use. The company also offers prepaid storage plans, annual storage contracts, and related laboratory services. A significant portion of recurring revenue is derived from long-duration storage agreements tied to preserved biological specimens.

The company’s operations are concentrated in the United States, though it has historically maintained international licensing and distribution relationships in select foreign markets. Cryo-Cell controls proprietary laboratory processing methods and maintains cryogenic storage facilities designed for long-term specimen viability. The company has referenced technologies associated with stem cell expansion and cellular therapeutics through collaborations and licensing arrangements, though commercial-scale therapeutic deployment remains limited. Public filings identify Cryo-Cell Processing and Storage Center operations as central assets supporting its service platform.

Strategic Position & Investments

Cryo-Cell’s strategic direction has focused on expanding stem cell preservation offerings and increasing participation in regenerative medicine-related opportunities. The company has invested in laboratory capabilities, specimen storage infrastructure, and intellectual property associated with stem cell processing technologies. Management has also emphasized customer retention through long-term storage contracts and expansion of cord tissue preservation services beyond traditional cord blood banking.

The company has pursued strategic relationships connected to cellular therapeutics and stem-cell applications, including prior involvement with technologies aimed at stem cell expansion and regenerative medicine research. Cryo-Cell has also explored opportunities tied to family banking awareness and physician referral networks. While the company participates in a niche segment of the healthcare services market, public disclosures indicate that broader commercialization of regenerative therapies remains dependent on evolving clinical evidence, regulatory developments, and adoption trends within the biotechnology sector.

Geographic Footprint

Cryo-Cell International is headquartered in Florida, United States, and its primary operational footprint remains concentrated in the domestic U.S. market. The company serves customers across the United States through physician networks, hospitals, childbirth educators, and direct consumer marketing initiatives. Its laboratory and storage operations are centralized to support nationwide specimen processing and preservation.

Historically, the company has maintained relationships in select international markets through licensing and distribution arrangements, including parts of Asia, Latin America, and the Middle East. However, publicly available information indicates that international operations represent a smaller portion of overall activity compared with the U.S. business. Data regarding the scale of current international revenue contribution is inconclusive based on available public sources.

Leadership & Governance

Cryo-Cell International operates under a corporate governance structure led by executive management and a board of directors overseeing strategy, compliance, financial performance, and operational execution. Leadership has historically emphasized long-term specimen preservation reliability, regulatory compliance, and positioning the company within the evolving regenerative medicine landscape. Public filings and investor materials indicate a strategic focus on operational efficiency, customer retention, and expansion of stem cell banking awareness.

Key executives identified in recent public disclosures include:

• David Portnoy – Chairman, Chief Executive Officer, and President
• Robert J. Woods – Chief Financial Officer
• Mark Portnoy – Vice President
• Prema Nair – Vice President, Laboratory Operations

Leadership and governance information is based primarily on company filings, including SEC filings, and related corporate disclosures. Certain executive responsibilities and organizational structures may change over time based on board actions or corporate updates.